The University of Wisconsin Comprehensive Cancer Center (UWCCC) was established in 1973 as a comprehensive, matrix center. By fostering and coordinating cancer research, it plays a leading role in the Medical School, on campus and in the region. Its 167 members, from 38 departments and eight different University schools participate in nine research programs: Breast Cancer, Urologic Cancer, Cell Adhesion and Signaling, Ocular Tumors, Immunology and Biological Therapeutics, Radiation Oncology and Physics, Developmental Therapeutics, Pediatric Oncology and Cancer Control. These programs encompass laboratory, clinical and population- based research and emphasize translation. Members have explored in laboratory and clinic the use and mechanisms of such anti-cancer agents as fluorouracil, perillyl alcohol, interferon, interleukin 2, monoclonal antibodies, tamoxifen and difluoromethylornithine. They have made fundamental discoveries about bladder, colon, and breast cancer etiology and the mechanisms of malignant transformation. Members' pain control projects have lead to cancer pain initiatives now located in every state and impacting internationally. Epidemiologic studies of women in Wisconsin have revealed modifiable factors that may decrease the risk of breast and bowel cancers. UWCCC has created a supportive environment for new and established investigators. Nine shared resources and the center's space, computing infrastructure, and common equipment serve members effectively. Biostatistics and the Clinical Trials Research Office are model shared resource. Flow Cytometry, the Analytical Laboratory, the Transgenic Animal and Scientific Instrumentation Facilities benefit many programs and projects. The present application, under new UWCCC Director John E. Niederhuber, M.D., requests renewal of comprehensive status and three years of support for key leaders, staff investigators, shared resources, and planning and evaluation. It describes the planned merger with McArdle Laboratory for Cancer Research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014520-27S2
Application #
6144083
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1976-01-01
Project End
2001-03-31
Budget Start
1999-04-16
Budget End
2000-03-31
Support Year
27
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Wisconsin Madison
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Xu, Cheng; Chen, Feng; Valdovinos, Hector F et al. (2018) Bacteria-like mesoporous silica-coated gold nanorods for positron emission tomography and photoacoustic imaging-guided chemo-photothermal combined therapy. Biomaterials 165:56-65
Wargowski, Ellen; Johnson, Laura E; Eickhoff, Jens C et al. (2018) Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine. J Immunother Cancer 6:21
Bednarz, Bryan; Grudzinski, Joseph; Marsh, Ian et al. (2018) Murine-specific Internal Dosimetry for Preclinical Investigations of Imaging and Therapeutic Agents. Health Phys 114:450-459
Romero-Masters, James C; Ohashi, Makoto; Djavadian, Reza et al. (2018) An EBNA3C-deleted Epstein-Barr virus (EBV) mutant causes B-cell lymphomas with delayed onset in a cord blood-humanized mouse model. PLoS Pathog 14:e1007221
van den Broek, Jeroen J; van Ravesteyn, Nicolien T; Mandelblatt, Jeanne S et al. (2018) Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49. Med Decis Making 38:140S-150S
Lu, Zhanping; Hong, Courtney C; Kong, Guangyao et al. (2018) Polycomb Group Protein YY1 Is an Essential Regulator of Hematopoietic Stem Cell Quiescence. Cell Rep 22:1545-1559
Shea, Michael P; O'Leary, Kathleen A; Fakhraldeen, Saja A et al. (2018) Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ER?+ Mammary Carcinomas. Cancer Res 78:1672-1684
Schrager, Sarina; Burnside, Elizabeth (2018) Breast Cancer Screening in Primary Care: A Call for Development and Validation of Patient-Oriented Shared Decision-Making Tools. J Womens Health (Larchmt) :
Ehlerding, Emily B; Grodzinski, Piotr; Cai, Weibo et al. (2018) Big Potential from Small Agents: Nanoparticles for Imaging-Based Companion Diagnostics. ACS Nano 12:2106-2121
Liu, Bai; Jones, Monica; Kong, Lin et al. (2018) Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models. Cytokine 107:105-112

Showing the most recent 10 out of 1528 publications